UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a)
of the Securities Exchange Act of 1934
(Amendment No. )
|
|
|
Filed by the Registrant
|
|
þ |
Filed by a Party other than the Registrant
|
|
o |
Check the appropriate box:
|
|
|
o
|
|
Preliminary Proxy Statement |
o
|
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
o
|
|
Definitive Proxy Statement |
þ
|
|
Definitive Additional Materials |
o
|
|
Soliciting Material Pursuant to § 240.14a-12 |
VALEANT PHARMACEUTICALS INTERNATIONAL
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)
Payment of Filing Fee (Check the appropriate box)
|
|
|
þ
|
|
No fee required. |
o
|
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. |
|
|
|
1.
|
|
Title of each class of securities to which transaction applies: |
|
|
|
|
|
|
|
2.
|
|
Aggregate number of securities to which transaction applies: |
|
|
|
|
|
|
|
3.
|
|
Per unit price or other underlying value of transaction computed pursuant to Exchange Act
Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was
determined): |
|
|
|
|
|
|
|
4.
|
|
Proposed maximum aggregate value of transaction: |
|
|
|
|
|
|
|
5.
|
|
Total fee paid: |
|
|
|
|
|
|
|
o
|
|
Fee paid previously with preliminary materials. |
|
|
|
o
|
|
Check box if any part of the fee is offset as provided by Exchange
Act Rule 0-11(a)(2) and identify the filing for which the
offsetting fee was paid previously. Identify the previous filing
by registration statement number, or the Form or Schedule and the
date of its filing. |
|
|
|
1.
|
|
Amount Previously Paid: |
|
|
|
|
|
|
|
2.
|
|
Form, Schedule or Registration Statement No.: |
|
|
|
|
|
|
|
3.
|
|
Filing Party: |
|
|
|
|
|
|
|
4.
|
|
Date Filed: |
|
|
|
|
Valeant Pharmaceuticals International
Additional Proxy Materials
March 31, 2009
Effective as of March 25, 2009, Stephen F. Stefano was elected by the Board of Directors (the
Board) of Valeant Pharmaceuticals International (the Company) to fill an open Board position in
the class expiring in 2010. There was no arrangement or understanding pursuant to which Mr. Stefano
was selected as a director.
In October 2008, the Company entered into an exclusive worldwide collaboration with Glaxo Group
Limited, a wholly owned subsidiary of GlaxoSmithKline plc (GSK), for the investigational drug
retigabine and certain backup compounds. Pursuant to the arrangement, GSK paid the Company an
upfront payment of $125 million, and GSK will pay the Company up to an additional $545 million upon
the achievement of certain milestones with respect to retigabine and up to an additional $150
million upon the achievement of certain milestones with respect to the backup compounds. The
Company will also share up to 50% of net profits from the sales of retigabine within the United
States, Australia, New Zealand, Canada and Puerto Rico, and will receive up to a 20% royalty on net
sales of retigabine outside those regions. In addition, if backup compounds are developed and
commercialized by GSK, GSK will pay the Company royalties of up to 20% of net sales of products
based upon such backup compounds. Other than the foregoing, the Company is not aware of any
transaction requiring disclosure under Item 404(a) of Regulation S-K.
Mr. Stefanos compensation as a director will be pursuant to the Companys standard non-employee
director compensation policy in effect from time to time. Pursuant to the Companys current
standard policy regarding non-employee director compensation, a director is entitled to receive a
grant of restricted stock units on the date of each annual meeting equal to the lesser of: (a)
$120,000 divided by the per share fair market value on the date of grant, or (b) the economic value
of options to purchase 25,000 shares of stock (as calculated using the Black-Scholes option pricing
method), assuming a strike price equal to the per share fair market value on the date of grant.
Under the current policy, the Company pays a director for such directors service as a Board member
an annual retainer of $30,000, a per meeting fee of $1,500 for meetings attended in person and $750
for meetings attended by telephone. A director will also be reimbursed for out-of-pocket expenses
in attending meetings and will be paid a $1,500 per diem ($750 for four hours or less) for services
rendered to the Company in his capacity as a director apart from meetings under the Companys
existing policies regarding compensation of its directors.
On March 26, 2009, the Company mailed to its stockholders a notice regarding the Internet
availability of its proxy materials relating to its 2009 Annual Meeting of Stockholders to be held
at 9:00 a.m., local time, on Tuesday, May 12, 2009 at the Hilton Hotel located at 41 John F.
Kennedy Parkway, Short Hills, New Jersey 07078. Below is certain information that would have been
included in the proxy materials regarding Mr. Stefano if Mr. Stefano had been elected as a director
in time to include such information in the proxy materials. This information updates and
supplements our proxy statement.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year First |
|
Other |
|
|
|
|
|
|
Serving as |
|
Public Company |
Name and Principal Occupation |
|
Age |
|
Director |
|
Directorships |
Stephen F. Stefano
|
|
|
53 |
|
|
|
2009 |
|
|
None |
|
|
|
|
|
|
|
|
|
|
|
Mr. Stefano has been Senior
Vice President of GSKs
Payor Markets Division since
January 2001 and has spent
23 years leading GSKs
Managed Markets Division. |
|
|
|
|
|
|
|
|
|
|
Mr. Stefano is not related by blood, marriage or adoption to any other Company director or to any
of the Companys executive officers.
Mr. Stefano does not beneficially own any shares of the Companys common stock.